TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Radiopharm Theranostics Limited Sponsored ADR ( (RADX) ) is now available.
On December 3, 2025, Radiopharm Theranostics Limited announced the successful outcome of its General Meeting, where all proposed resolutions were approved by poll. The resolutions included the ratification of prior issue of shares and the approval of new share issuances and options, indicating strong shareholder support and potentially enhancing the company’s capital structure. This development could positively impact the company’s strategic initiatives and market positioning, reinforcing its commitment to advancing its radiopharmaceutical projects.
The most recent analyst rating on (RADX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited Sponsored ADR stock, see the RADX Stock Forecast page.
More about Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited operates in the medical industry, focusing on the development and commercialization of radiopharmaceutical products for diagnostic and therapeutic purposes. The company is primarily engaged in providing innovative solutions in the field of cancer treatment, leveraging advanced radiopharmaceutical technologies to improve patient outcomes.
Average Trading Volume: 26,899
Technical Sentiment Signal: Strong Sell
Current Market Cap: $40.43M
For an in-depth examination of RADX stock, go to TipRanks’ Overview page.